{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:57:46Z","timestamp":1787169466330,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.vaccine.2018.04.007","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T01:48:23Z","timestamp":1523411303000},"page":"2774-2782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A toddler PCV booster dose following 3 infancy priming doses increases circulating serotype-specific IGG levels but does not increase protection against carriage"],"prefix":"10.1016","volume":"36","author":[{"given":"Ron","family":"Dagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalom","family":"Ben-Shimol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Simell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurith","family":"Porat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"K\u00e4yhty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noga","family":"Givon-Lavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.vaccine.2018.04.007_b0005","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.04.007_b0010","doi-asserted-by":"crossref","unstructured":"De Carvalho Gomes H, Muscat M, Monnet DL, Giesecke J, Lopalco PL. Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001\u20132007. Euro Surveill 2009;14(12).","DOI":"10.2807\/ese.14.18.19200-en"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.04.007_b8050","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1097\/INF.0000000000000076","article-title":"Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers","volume":"33","author":"Whitney","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.04.007_b0015","first-page":"129","article-title":"2012","volume":"87","author":"Pneumococcal vaccines WHO position paper","year":"2012","journal-title":"Week Epidemiol Rec"},{"issue":"8","key":"10.1016\/j.vaccine.2018.04.007_b0020","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/INF.0b013e3181d99345","article-title":"Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine \u2013 a randomized controlled trial","volume":"29","author":"Givon-Lavi","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.vaccine.2018.04.007_b0025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1586\/erv.11.11","article-title":"Pneumococcal polysaccharide-protein (CRM197) conjugate vaccines, 7- or 9-valent, in the 2 + 1 schedule","volume":"10","author":"Fritzell","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2018.04.007_b0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jama.2009.975","article-title":"Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial","volume":"302","author":"van Gils","year":"2009","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.vaccine.2018.04.007_b0035","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1128\/CVI.00117-10","article-title":"Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster","volume":"17","author":"Russell","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"41","key":"10.1016\/j.vaccine.2018.04.007_b0040","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1016\/j.vaccine.2009.06.098","article-title":"Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine","volume":"27","author":"Russell","year":"2009","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2018.04.007_b0045","doi-asserted-by":"crossref","first-page":"9711","DOI":"10.1016\/j.vaccine.2011.07.042","article-title":"Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis","volume":"29","author":"Scott","year":"2011","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2018.04.007_b0050","doi-asserted-by":"crossref","first-page":"9600","DOI":"10.1016\/j.vaccine.2011.09.011","article-title":"Immunogenicity of pneumococcal conjugate vaccines in infants after two or three primary vaccinations: a systematic review and meta-analysis","volume":"29","author":"Ruckinger","year":"2011","journal-title":"Vaccine"},{"issue":"34","key":"10.1016\/j.vaccine.2018.04.007_b0055","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1016\/j.vaccine.2012.05.059","article-title":"The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial","volume":"30","author":"Dagan","year":"2012","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.vaccine.2018.04.007_b0060","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1016\/j.vaccine.2011.01.098","article-title":"The immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine immunization schedule","volume":"29","author":"Ota","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.007_b0065","unstructured":"Conklin L, Deloria Knoll M, Loo JD, Fleming-Dutra KE, Park DE, Scott Johnson T, et al. Landscape analysis of pneumococcal conjugate vaccine dosing schedules: a systematic review. Sub-report on the 3-dose schedules. A project of the AVI technical assistance consortium (AVI-TAC) Final report 1.0, 17 October 2011. <http:\/\/www.who.int\/immunization\/sage\/3_Conklin_L_PCV_Dosing_Landscape_Report_Oct_17_2011_FINAL_nov11.pdf> [accessed December 2017]."},{"issue":"8","key":"10.1016\/j.vaccine.2018.04.007_b0070","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1086\/591967","article-title":"Reduction of carriage and transmission of Streptococcus pneumoniae: the beneficial \u201cside effect\u201d of pneumococcal conjugate vaccine","volume":"47","author":"Azzari","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2018.04.007_b0075","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1586\/14760584.5.5.651","article-title":"(PneumoCarr) atPCG. Nasopharyngeal colonization: a target for pneumococcal vaccination","volume":"5","author":"Kayhty","year":"2006","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2018.04.007_b0080","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2018.04.007_b0085","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1086\/315009","article-title":"Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine","volume":"180","author":"Mbelle","year":"1999","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2018.04.007_b0090","doi-asserted-by":"crossref","first-page":"e1001107","DOI":"10.1371\/journal.pmed.1001107","article-title":"Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial","volume":"8","author":"Roca","year":"2011","journal-title":"PLoS Med"},{"issue":"11","key":"10.1016\/j.vaccine.2018.04.007_b0095","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1086\/522164","article-title":"Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae\u2013and associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization\u2013in HIV-infected and HIV-uninfected children","volume":"196","author":"Madhi","year":"2007","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2018.04.007_b0100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.33321\/cdi.2008.32.3","article-title":"Invasive pneumococcal disease in Australia, 2006","volume":"32","author":"Roche","year":"2008","journal-title":"Commun Dis Intell"},{"issue":"2","key":"10.1016\/j.vaccine.2018.04.007_b0105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/cid\/ciw720","article-title":"Long-term impact of a \u201c3 + 0\u201d schedule for 7- and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in Australia, 2002\u20132014","volume":"64","author":"Jayasinghe","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.007_b0110","unstructured":"Statistical Abstracts of Israel, No. 49. Central Bureau of Statistics. Jerusalem: Hemed Press Ltd.; 1998."},{"issue":"2","key":"10.1016\/j.vaccine.2018.04.007_b0115","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/21645515.2015.1095414","article-title":"Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel","volume":"12","author":"Ben-Shimol","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2018.04.007_b0120","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3201\/eid1106.050198","article-title":"Community prescribing and resistant Streptococcus pneumoniae","volume":"11","author":"Barkai","year":"2005","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2018.04.007_b0125","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CDLI.2.5.590-597.1995","article-title":"Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S","volume":"2","author":"Quataert","year":"1995","journal-title":"Clin Diagn Lab Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2018.04.007_b0130","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1128\/CDLI.8.2.266-272.2001","article-title":"Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay","volume":"8","author":"Concepcion","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2018.04.007_b0135","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1128\/CDLI.11.6.1064-1069.2004","article-title":"Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(f)","volume":"11","author":"Quataert","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2018.04.007_b0140","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1128\/CVI.00112-06","article-title":"Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies","volume":"13","author":"Burton","year":"2006","journal-title":"Clin Vaccine Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2018.04.007_b0145","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.vaccine.2010.12.121","article-title":"Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis","volume":"29","author":"Simell","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.04.007_b0150","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1086\/431524","article-title":"Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study","volume":"192","author":"Goldblatt","year":"2005","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2018.04.007_b0155","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1086\/513199","article-title":"Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine","volume":"44","author":"Millar","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2018.04.007_b0160","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1086\/431679","article-title":"Serum serotype-specific pneumococcal anticapsular immunoglobulin G concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus","volume":"192","author":"Dagan","year":"2005","journal-title":"J Infect Dis"},{"issue":"36","key":"10.1016\/j.vaccine.2018.04.007_b0165","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1016\/j.vaccine.2016.06.075","article-title":"Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration","volume":"34","author":"Dagan","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.007_b0170","doi-asserted-by":"crossref","unstructured":"Fleming-Dutra KE, Conklin L, Loo JD, Knoll MD, Park DE, Kirk J, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage. Pediatr Infect Dis J 2014;33 Suppl 2:S152\u201360.","DOI":"10.1097\/INF.0000000000000083"},{"issue":"12","key":"10.1016\/j.vaccine.2018.04.007_b0175","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1164\/rccm.201512-2467OC","article-title":"Polysaccharide-specific memory B cells predict protection against experimental human pneumococcal carriage","volume":"194","author":"Pennington","year":"2016","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18304766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18304766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T11:39:00Z","timestamp":1751542740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18304766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":36,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0264410X18304766"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.007","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A toddler PCV booster dose following 3 infancy priming doses increases circulating serotype-specific IGG levels but does not increase protection against carriage","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}